Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | APEX1 | P27695 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707205 | 1.00 | MAPT (0.43) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL3111746 | 1.00 | MAPT (0.43) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL17897722 | 0.94 | MAPT (0.42) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL17528778 | 0.93 | MAPT (0.44) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL22449554 | 0.93 | MAPT (0.44) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL12968453 | 0.91 | CTDSP1 (0.39) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL9587073 | 0.90 | NR1I2 (0.51) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL9587077 | 0.90 | NR1I2 (0.51) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL12968958 | 0.90 | NR1I2 (0.56) | MAPTNR1I2PPARGALBSLC22A6 | |
| SCHEMBL21307548 | 0.90 | NR1I2 (0.56) | MAPTNR1I2PPARGALBSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468968-B1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | MERCK SHARP & DOHME LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11542279-B2 | Solid forms of ceftolozane and processes for preparing | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220056045-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| US-10941161-B2 | Intermediates in the synthesis of cephalosporin compounds | MERCK SHARP & DOHME CORP. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190225624-A1 | INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10221196-B2 | Intermediates in the synthesis of cephalosporin compounds | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017213944-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170226126-A1 | INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226126-A1 | INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | ASTELLAS PHARMA INC. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| US-20050004094-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | MAPT 2537/4885NR1I2 603/4885PPARG 4409/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | MAPT 3238/4885NR1I2 385/4885PPARG 4512/4885 |
| US-20050004094-A1 | Cephem compounds | CEP170, C1S, CEPT1 | MAPT 2548/4885NR1I2 617/4885PPARG 3350/4885 |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | UROD, PEPD, CMPK1 | MAPT 1190/4885NR1I2 906/4885PPARG 316/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | MAPT 3569/4885NR1I2 624/4885PPARG 3887/4885 |
| US-20190225624-A1 | INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | RCSD1, PYCARD, CTRC | MAPT 2093/4885NR1I2 1727/4885PPARG 3313/4885 |
| US-11542279-B2 | Solid forms of ceftolozane and processes for preparing | PPP1CC, CCNC, AMPD3 | MAPT 2921/4885NR1I2 3016/4885PPARG 3202/4885 |
| US-10221196-B2 | Intermediates in the synthesis of cephalosporin compounds | CTRC, DCXR, XDH | MAPT 4489/4885NR1I2 767/4885PPARG 1185/4885 |
| US-20220056045-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | PPP1CC, CCNC, AMPD3 | MAPT 2921/4885NR1I2 3016/4885PPARG 3202/4885 |
| US-20170226126-A1 | INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS | CTRC, XDH, DCXR | MAPT 4446/4885NR1I2 1066/4885PPARG 1862/4885 |
| US-10941161-B2 | Intermediates in the synthesis of cephalosporin compounds | RCSD1, PYCARD, CTRC | MAPT 2093/4885NR1I2 1727/4885PPARG 3313/4885 |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | CEP170, Q6ZSR9, H1-10 | MAPT 4139/4885NR1I2 899/4885PPARG 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.